Camarda Financial Advisors’s Quest Diagnostics DGX Stock Holding History

Camarda Financial Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,751	Closed	-$995K	–	107
2021 Q4	$995K	Sell	5,751 -715	-11%	-$109K	0.56%	21
2021 Q3	$940K	Sell	6,466 -713	-10%	-$104K	0.63%	17
2021 Q2	$947K	Sell	7,179 -50	-0.7%	-$6.55K	0.59%	42
2021 Q1	$928K	Buy	+7,229	New	+$891K	0.66%	40
2017 Q1	–	Sell	-15,167	Closed	-$1.39M	–	197
2016 Q4	$1.39M	Sell	15,167 -694	-4%	-$59.8K	0.95%	48
2016 Q3	$1.34M	Buy	+15,861	New	+$1.33M	0.82%	52

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Camarda Financial Advisors's DGX Position: Q1 2022 in Review

Camarda Financial Advisors sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 5,751 shares — an estimated $995K sold.

Camarda Financial Advisors first reported a position in DGX in Q3 2016 and held it in 6 quarters. The position peaked at $1.39M in Q4 2016. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

Camarda Financial Advisors reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
Camarda Financial Advisors sold 5,751 Quest Diagnostics shares in Q1 2022, an estimated $995K.
Camarda Financial Advisors first reported a position in Quest Diagnostics in Q3 2016 and held it in 6 quarters.
Camarda Financial Advisors's Quest Diagnostics position peaked at $1.39M in Q4 2016.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Camarda Financial Advisors's 13F filing for Q1 2022, filed 10 May 2022.